MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy. The Company was formed in 2010 through an investment from the Medical Research Commercialisation Fund (MRCF). The Company’s published research shows that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signaling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.
miR-7: An anti-cancer micro RNA
Leading Biology….. A New Weapon for Cancer
MiReven is commercialising the pioneering work of Prof Peter Leedman and Dr Keith Giles at the Harry Perkins Institute of Medical Research on the anti-cancer potential of miR-7.
- miReven Scientists Awarded $530k Grant to Advance miR-7 Cancer Therapeutic 19 November 2015
- microRNA-7: A tumor suppressor miRNA with therapeutic potential 24 July 2014
- MiReven Receives United States Patent 30 April 2014
- MiReven Wins 2013 Western Australia Innovator of the Year Award 14 November 2013